Could you be
Halt-MS is sponsored by the
National Institute of Allergy
and Infectious Diseases (a part
of the National Institutes of
Health) and is being conducted
by the Immune Tolerance
© 2007-9, Immune Tolerance Network
HALT-MS is an NIH-sponsored clinical trial evaluating autologous stem cell transplantation for poor prognosis MS.
Peripheral blood stem cells (CD34+) are mobilized with G-CSF and prednisone, and collected.
Between 7-14 days later, participants are treated with a intensive conditioning regimen of BEAM (carmustine, etoposide, cytosine arabinoside and melphalan) + Thymoglobulin. The BEAM protocol followed by CD34-selected stem cell transplantation. Participants will remain hospitalized until the recovery of peripheral blood cell counts.
In a recently published Italian study, 18 of 19 patients with high disease activity and sustained clinical deterioration showed clinical stabilization or improvement following BEAM/rATG and autologous HCT .
The study is open to individuals 18-60 years of age, who:
Patients with primary progressive MS or secondary progressive MS without relapses for 12 or more months are not eligible. Patients must not have HIV, active hepatitis B or C infection or cirrhosis to be eligible.
*** ENROLLMENT IN the Halt-MS Study is NOW CLOSED ***
Physician Quick Reference Card*
Adobe .pdf (93 kb)
* requires Adobe Acrobat Reader. Get it here.